QUANTEL MEDICAL ESTABLISHES INTERNATIONAL LASER ADVISORY BOARD

Protocol for Subthreshold MicroPulse™ Laser Treatment of Diabetic Macular Edema Introduced

Clermont-Ferrand, France – June 24, 2014 – Quantel Medical today announced a treatment guideline for the use of subthreshold MicroPulse™ laser for treating diabetic macular edema using Quantel’s SupraScan™ 577 laser platform. The introduction of the treatment guideline is the first step to initiating a multi-center study design in which all participating sites can perform the laser treatment under the same parameters. The study design will have two main objectives; one, to achieve improved patient care for DME patients in the era of anti-VEGF treatments, and two, establish the indications for use and the optimum subthreshold MicroPulse laser treatment parameters to be used.

Quantel’s Advisory Board Chairman, Professor Victor Chong, MD, FRCS, FRCOphth, Oxford Eye Hospital, initiated the creation of the treatment guidelines working with the SupraScan 577. Professor Chong presented the initial results of a histological study at ARVO in May 2014. The histological animal study was a key milestone in establishing the criteria for the treatment guidelines, including clinical validation of the preferred wavelength to use, the recommended duty cycle to use, and the optimum “dosage” of energy for MicroPulse delivery. This study confirmed the clinical findings that retina was best preserved by using MicroPulse subthreshold laser photocoagulation with the 577nm wavelength, a 5% duty cycle and by reducing power to 50% of threshold power.

Quantel’s establishment of their international laser advisory board and the introduction of a formal treatment guideline demonstrate a significant step in supporting their ophthalmologist customers in improving patient care. Jean-Marc Gendre, CEO of Quantel Medical, commented: “Our long-term goal is to establish the ongoing importance and role of laser in the treatment of retina diseases. With a common protocol, we can now develop the clinical studies necessary to produce the data for this goal. Working with our KOL’s we are confident that we can support their management of their DME patients.”

Quantel's SupraScan 577 laser is the ideal platform to be used in this study due to its 577nm yellow wavelength, offering ideal energy absorption, and its multispot delivery mode, offering uniform placement and homogeneous laser impacts across the intended targets. These two advanced features combined with MicroPulse delivery mode provide the most advanced laser platform for treating retina diseases.

About Quantel Medical

Founded in 1993 and headquartered in Clermont-Ferrand, France, Quantel Medical is a global ophthalmic medical device company dedicated to developing leading technologies to improve the treatment of ocular diseases. Quantel Medical has a strong emphasis in research and development, resulting in many first-to-market product introductions and a comprehensive product portfolio of diagnostic ultrasound and surgical lasers for ophthalmologists. These products are available through
direct sales operations in the U.S. and France, and through independent distributors in over 80 countries.

Quantel Medical is a division of Quantel (QUA:EN), a world-wide leader in the development of solid-state lasers for scientific and industrial applications. For more information, please visit www.quantel-medical.com.

References


MicroPulse™ is a trademark of IRIDEX Corporation and may not be used without permission.

###